DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
For breast cancer patients who are candidates to receive chemotherapy, concurrent use of
temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) can be
offered as ovarian protection.
Because ovarian stimulation for oocyte cryopreservation is usually performed using a GnRH
antagonist protocol and typically involves final oocyte maturation triggering with a GnRH
agonist, the investigators designed this study to explore the feasibility of combining the
final oocyte maturation trigger and the start of ovarian suppression. Short-term cotreatment
with GnRH antagonists is needed to induce rapid luteolysis (in view of prevention of ovarian
hyperstimulation).
To demonstrate the safety of GnRH agonist depot triggering followed by daily GnRH antagonist
luteolysis, this pilot study is set out to analyse the endocrine profile and ovarian
morphology of this novel protocol.